Regulatory Pathways, Development Challenges and Market Access for Inhaled Products in China
Hou S, Li Y, Ye X, Shen A.
RDD Asia 2014. Volume , 2014: 131-142.
Abstract:
Rapid growth in the use of inhaled drugs in China, coupled with increased inhaled drug development, offers a great potential for domestic and international pharmaceutical companies. To take advantage of this potential growth, however, it is important to understand not only the regulatory pathways for drug development and registration, but also China’s medical insurance system, patient access to hospitals and medicines, and the trends in clinical use of inhaled drugs in China. This article aims to help companies operating in this dynamic environment to develop strategies that address the growing needs of patients and healthcare providers for respiratory drug products in China.
I have a subscription
Log in for instant access.
I do not have a subscription
Purchase Article (in PDF format)
